Avanos Medical (NYSE:AVNS) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Avanos Medical (NYSE:AVNS) from a strong-buy rating to a buy rating in a research note released on Saturday.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. Zacks Research upgraded shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce”.

Avanos Medical Price Performance

AVNS stock opened at $14.12 on Friday. The stock has a market capitalization of $656.44 million, a price-to-earnings ratio of -8.93 and a beta of 1.09. The company has a quick ratio of 1.36, a current ratio of 2.15 and a debt-to-equity ratio of 0.12. Avanos Medical has a 52-week low of $9.30 and a 52-week high of $15.68. The stock’s fifty day simple moving average is $13.05 and its 200-day simple moving average is $12.11.

Avanos Medical (NYSE:AVNS) last released its earnings results on Tuesday, February 24th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.24 by $0.05. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The firm had revenue of $180.90 million during the quarter, compared to analyst estimates of $174.70 million. During the same period in the prior year, the firm posted $0.43 earnings per share. The business’s quarterly revenue was up .7% compared to the same quarter last year. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Equities research analysts expect that Avanos Medical will post 1.32 EPS for the current year.

Institutional Trading of Avanos Medical

Institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC acquired a new position in shares of Avanos Medical in the second quarter worth about $1,145,000. Thrivent Financial for Lutherans grew its stake in Avanos Medical by 352.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 153,764 shares of the company’s stock valued at $1,778,000 after purchasing an additional 119,760 shares in the last quarter. Clark Estates Inc. NY increased its holdings in Avanos Medical by 58.7% during the 3rd quarter. Clark Estates Inc. NY now owns 783,880 shares of the company’s stock worth $9,062,000 after purchasing an additional 290,000 shares during the last quarter. Diamond Hill Capital Management Inc. increased its holdings in Avanos Medical by 26.0% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 434,661 shares of the company’s stock worth $5,025,000 after purchasing an additional 89,630 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of Avanos Medical in the 2nd quarter valued at approximately $3,212,000. 95.17% of the stock is owned by hedge funds and other institutional investors.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.